A Phase 1 Study of Blinatumomab in Combination With Checkpoint Inhibitor(s) of PD-1 (Nivolumab) or Both PD-1 (Nivolumab) and CTLA-4 (Ipilimumab) in Patients With Poor-Risk, Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia
Latest Information Update: 21 Oct 2024
At a glance
- Drugs Blinatumomab (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Acute biphenotypic leukaemia; Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- 16 Oct 2024 Planned End Date changed from 6 Sep 2024 to 18 Jul 2025.
- 12 Dec 2023 Results presented at the 65th American Society of Hematology Annual Meeting and Exposition, based on safety and efficacy data, blina + nivo was expanded to include 6 additional pts without additional DLTs. Ongoing analyses of changes in T cell subpopulations, co-signaling molecule expression, and single cell RNA seq results will be presented.
- 12 Dec 2023 Results reporting efficacy and safety data presented at the 65th American Society of Hematology Annual Meeting and Exposition